Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Primary vitreoretinal lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
30 July 2026
2026 Primary vitreoretinal lymphoma indication strategy covering epidemiology, BTK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Testicular lymphoma Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Testicular lymphoma indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Fumarate hydratase-deficient renal cell carcinoma Indication Strategy Report 2026: HIF2A, Trials and Deals
30 July 2026
2026 Fumarate hydratase-deficient renal cell carcinoma indication strategy covering epidemiology, HIF2A biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
MiT family translocation renal cell carcinoma Indication Strategy Report 2026: TFE3, Trials and Deals
30 July 2026
2026 MiT family translocation renal cell carcinoma indication strategy covering epidemiology, TFE3 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Oncocytic renal neoplasm Indication Strategy Report 2026: mTOR, Trials and Deals
30 July 2026
2026 Oncocytic renal neoplasm indication strategy covering epidemiology, mTOR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Collecting duct carcinoma Indication Strategy Report 2026: MET, Trials and Deals
30 July 2026
2026 Collecting duct carcinoma indication strategy covering epidemiology, MET biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Urinary tract small cell carcinoma Indication Strategy Report 2026: DLL3, Trials and Deals
30 July 2026
2026 Urinary tract small cell carcinoma indication strategy covering epidemiology, DLL3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Extramammary Paget disease Indication Strategy Report 2026: HER2, Trials and Deals
30 July 2026
2026 Extramammary Paget disease indication strategy covering epidemiology, HER2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Urethral carcinoma Indication Strategy Report 2026: FGFR3, Trials and Deals
30 July 2026
2026 Urethral carcinoma indication strategy covering epidemiology, FGFR3 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Vulvar Paget disease Indication Strategy Report 2026: HER2, Trials and Deals
30 July 2026
2026 Vulvar Paget disease indication strategy covering epidemiology, HER2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Vulvar melanoma Indication Strategy Report 2026: KIT, Trials and Deals
30 July 2026
2026 Vulvar melanoma indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Mesonephric adenocarcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
30 July 2026
2026 Mesonephric adenocarcinoma indication strategy covering epidemiology, KRAS biology, active trials, transactions, unmet need, competition and market…